Depomed (DEPO) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RBC Reiterates Sector Perform Rating and $22 PT on Depomed (DEPO) Following 4Q Results, Ahead of 2/23 RBC Healthcare Conference
February 22, 2017 7:42 AM ESTRBC Capital Markets analyst Randall Stanicky reiterates Sector Perform rating and $22 price target on Depomed Inc. (NASDAQ: DEPO), suggesting the strategic outlook remains the focus, as the company reported 2016 fourth quarter revenue and EPS slightly above consensus. RBC Capital Markets will be hosting Depomed at the RBC Healthcare Conference on Thursday,... More
